Synapse - Andrew Zelenetz

Search Within

Andrew D Zelenetz

Results (785)

Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a phase 3 randomized double-blind placebo-controlled study

Meeting Abstract

Zelenetz, A. D.; Robak, T.; Coiffier, B.; Delgado, J.; Marlton, P.; Adewoye, A. H.; Kim, Y.; Dreiling, L. K.; Hillmen, P.
Blood (2015)

Fulltext@MSK | Save

A clinicogenetic risk model (m7-FLIPI) prospectively identifies one-half of patients with early disease progression of follicular lymphoma after first-line immunochemotherapy

Meeting Abstract

Vindi, J.; Kridel, R.; Staiger, A. M.; Szczepanowski, M.; Horn, H.; Dreyling, M. H.; Rosenwald, A.; Ott, G.; Klapper, W.; Zelenetz, A. D.; more...
Blood (2015)

Fulltext@MSK | Save

A phase 2 study of idelalisib monotherapy in previously untreated patients >= 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Meeting Abstract

Zelenetz, A.; Lamanna, N.; Kipps, T.; Coutre, S.; O'Brien, S.; Graves, J.; Ye, W.; Dubowy, R.; Flinn, I.
Leukemia and Lymphoma (2015)

Fulltext@MSK | Save

Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era

Journal Article

Kumar, A.; Lunning, M. A.; Zhang, Z.; Migliacci, J. C.; Moskowitz, C. H.; Zelenetz, A. D.
British Journal of Haematology (2015)

Fulltext@MSK | Save

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Journal Article

O'Brien, S. M.; Lamanna, N.; Kipps, T. J.; Flinn, I.; Zelenetz, A. D.; Burger, J. A.; Keating, M.; Mitra, S.; Holes, L.; Yu, A. S.; more...
Blood (2015)

Fulltext@MSK | Save

Outcomes of anticoagulant (AC) or antiplatelet (AP) use in patients (pts) with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin's lymphoma (iNHL) in idelalisib (IDELA) trials

Meeting Abstract

Stilgenbauer, S.; Barrientos, J.; Ghia, P.; Pagel, J.; Salles, G. A.; Sharman, J. P.; Gurtovaya, O.; Kim, Y.; Philip, B.; Zelenetz, A. D.
Oncology Research and Treatment (2015)

Fulltext@MSK | Save

Outcomes of anticoagulant or antiplatelet use in patients with chronic lymphocytic leukemia or indolent non-Hodgkin's lymphoma in idelalisib trials

Meeting Abstract

Ghia, P.; Carella, A. M.; Massaia, M.; Barrientos, J.; Pagel, J.; Salles, G.; Sharman, J. P.; Stilgenbauer, S.; Gurtovaya, O.; Kim, Y.; more...
Haematologica (2015)

Fulltext@MSK | Save

Management of adverse events associated with idelalisib treatment: Expert panel opinion

Journal Article

Coutre, S. E.; Barrientos, J. C.; Brown, J. R.; de Vos, S.; Furman, R. R.; Keating, M. J.; Li, D.; O'Brien, S. M.; Pagel, J. M.; Poleski, M. H.; more...
Leukemia and Lymphoma (2015)

Fulltext@MSK | Save

Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20(+) indolent B-cell non-Hodgkin lymphoma: Final analysis of the GAUSS study

Journal Article

Sehn, L. H.; Goy, A.; Offner, F. C.; Martinelli, G.; Caballero, M. D.; Gadeberg, O.; Baetz, T.; Zelenetz, A. D.; Gaidano, G.; Fayad, L. E.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Prognostic value of FDG PET/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma

Journal Article

Ulaner, G. A.; Goldman, D. A.; Sauter, C. S.; Migliacci, J.; Lilienstein, J.; Gönen, M.; Schöder, H.; Moskowitz, C. H.; Zelenetz, A. D.
Radiology (2015)

Fulltext@MSK | Save